Immuron path to profitability

In case you missed it, Immuron recently provided an update on its change in strategy at the same time as releasing half year financial results. These are available on our Investor Hub.

A summary of this strategic change outlined below was included in our most recent investor presentation to Coffee Microcaps.

Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization.

• IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s diarrhea)

  • Lumanity peak U.S. sales estimate of US$102 million

• IMM-529 has an investigational new drug (IND) application approved by the U.S. FDA and is ready to go into Phase 2 clinical trials (indication: Clostridioides difficile infection)

  • Lumanity peak U.S. sales estimate of US$400 million

• Under a partnering model, the licensee typically funds development, registration and commercialization costs and pays the licensor an upfront licensing fee, milestone payments and royalties on sales

• This partnering strategy removes the uncertainty of how Immuron would fund these assets through to commercialization

• Partnering has the potential to bring forward monetization of these assets

• The reduction in R&D expenses (net of R&D Tax Incentive) will improve profitability and decrease cash burn

• Immuron has sufficient cash ($10 million @ 31 December 2025) to fund commercial operations (over the counter (OTC) sales of Travelan® and PROIBS®

• Immuron continues to evaluate opportunities to broaden distribution and to add complementary products to its OTC portfolio

As a result of these announcements, Emerging Growth Research issued a research report on March 5. Please note the Important Disclosures in this report.

I look forward to providing you further updates as we execute our strategy.

Steven Lydeamore

Chief Executive Officer